Virus Or Component Thereof Patents (Class 424/204.1)
  • Patent number: 10660952
    Abstract: The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 26, 2020
    Inventors: Troy James Kaiser, Jeremy Kroll, Eric Martin Vaughn
  • Patent number: 10654899
    Abstract: The present invention relates to a protein comprising a truncated version of the HSV-2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or 95% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 19, 2020
    Assignee: SIMPLEXIA AB
    Inventor: Jan-Åke Liljeqvist
  • Patent number: 10620204
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the immunodetection methods described above.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 14, 2020
    Assignees: VANDERBILT UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James E. Crowe, Jr., Andrew I. Flyak, Alexander Bukreyev, Philipp Ilinykh
  • Patent number: 10583189
    Abstract: The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 10, 2020
    Assignee: Investigacion Aplicada, S.A. DE C.V.
    Inventors: Eduardo Lucio Decanini, José Andrés Morales Garzon
  • Patent number: 10576142
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: March 3, 2020
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10568955
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: February 25, 2020
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10548915
    Abstract: The present invention is related to a combination for treating an EV71 infection, which comprises two or more compounds at each's non-effective level and provides an unexpected synergistic activity against EV71 replication, wherein the compound is selected from the group consisting of auranofin, ouabain, emetine, niclosamide, and S-(+)-fluoxetine.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 4, 2020
    Assignee: SUN JET BIOTECHNOLOGY INC.
    Inventors: Yeou Guang Tsay, Szu-Hao Kung
  • Patent number: 10526376
    Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 7, 2020
    Assignee: University of Copenhagen
    Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
  • Patent number: 10500268
    Abstract: Disclosed are compositions and methods for related to mutant influenza viruses with increased fidelity.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: December 10, 2019
    Assignee: University of Rochester
    Inventors: Andrew Cox, Stephen Dewhurst
  • Patent number: 10472647
    Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: November 12, 2019
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Suzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
  • Patent number: 10443040
    Abstract: Disclosed in the present application are: a method for preparing in vitro/ex vivo antigen-specific cytotoxic T-cells by using B cells treated with biological response modifier; and a use thereof. The cytotoxic T-cells prepared by the method of the present application can be used advantageously for treating infectious disease and cancer and the like.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 15, 2019
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Hyoung Jin Kang, Sun Ok Yun, Chang-Yuil Kang
  • Patent number: 10435712
    Abstract: The present invention relates to the discovery of a high titer hybrid-virus vector that gives rise to high titer virus like vesicles (VLVs) that can be used as a vaccine. The invention includes compositions and methods of generating an evolved hybrid-virus vector vaccine and selecting high titer VLVs, methods of treating and/or preventing or immunizing against, a specific disease or disorder, and methods of inducing a memory T cell and B cell immune response in a subject administered the VLV composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a subject as well as a high titer protein expression system.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: October 8, 2019
    Assignee: Yale University
    Inventors: John Rose, Nina Rose
  • Patent number: 10426828
    Abstract: Pharmaceutical suspensions of multimeric-multiepitope influenza polypeptides, processes for their production and their use as immunizing subjects against influenza. In particular, stable aqueous microparticulate suspensions of a multimeric multiepitope polypeptide are disclosed.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: October 1, 2019
    Assignee: BIONDVAX PHARMACEUTICALS LTD.
    Inventors: Ram Uritski, Barry Cohen, Zohar Gadri, Shimon Hassin
  • Patent number: 10426829
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 1, 2019
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
  • Patent number: 10421978
    Abstract: The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: September 24, 2019
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Bernard Moss, Linda S. Wyatt, Patricia L. Earl
  • Patent number: 10385101
    Abstract: A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 20, 2019
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Patent number: 10329586
    Abstract: The present invention relates to the field of CAdV vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. Additionally, disclosed and claimed are truncated EHV4 promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Andreas Gallei, Ramesh Koukuntla, Robert Barry Mandell, Alice Mundt, Kristina Rehmet, Eric Martin Vaughn
  • Patent number: 10279028
    Abstract: Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 7, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Renukaradhya J. Gourapura, Varun Dwivedi, Basavaraj S. Binjawadagi, Jordi Torrelles
  • Patent number: 10253294
    Abstract: The present invention relates to a method for producing dendritic cells with increased capability to activate T cells, to dendritic cells obtainable by such a method, and to a pharmaceutical composition comprising such dendritic cells.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: April 9, 2019
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Marion Heuer, Manfred Lutz, Andreas Beilhack
  • Patent number: 10206993
    Abstract: This invention provides a multivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a Lawsonia intracellularis antigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 19, 2019
    Assignee: Zoetis Services LLC
    Inventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 10174084
    Abstract: The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: January 8, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventor: Takanori Sato
  • Patent number: 10144975
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: December 4, 2018
    Assignees: INSTITUT PASTEUR, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, PATHOQUEST, ECOLE NATIONALE VETERINAIRE D'ALFORT
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Patent number: 10130698
    Abstract: The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 20, 2018
    Assignee: Intervet Inc.
    Inventors: Vicky Fachinger, Melanie Sno, Maarten Hendrik Witvliet
  • Patent number: 10105440
    Abstract: In one aspect, the present disclosure provides compounds of formulae I and II. In another aspect, a compound of formula I or II is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 23, 2018
    Assignee: Variation Biotechnologies Inc.
    Inventor: Maura Ellen Campbell
  • Patent number: 10100101
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: October 16, 2018
    Assignee: Ohio State Innovation Foundation
    Inventor: Daral John Jackwood
  • Patent number: 10071150
    Abstract: An immunity enhancing therapeutic vaccine includes a gene vector based on recombinant adenovirus and three elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18, 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis, and 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The vaccine is used for the treatment of human papilloma virus infections and related diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: September 11, 2018
    Assignee: MYGT Biopharmaceutical LLC
    Inventors: Tao Bian, Juan Li, Xiao Xiao
  • Patent number: 10064924
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Kowalewski, Claudia Berlin
  • Patent number: 10052375
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 21, 2018
    Assignee: Zoetics Services LLC
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Patent number: 10039820
    Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 7, 2018
    Assignee: Hawaii Biotech, Inc.
    Inventors: Beth-Ann Coller, Vidya Pai, Carolyn L. Weeks-Levy, Steven A. Ogata
  • Patent number: 10034929
    Abstract: The disclosure provides recombinant viral vectors and attenuated viruses and viral vaccines comprising a virus lacking a functional viral RNA suppressor of host RNAi.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: July 31, 2018
    Assignee: The Regents of the University of California
    Inventors: Shou-Wei Ding, Yang Li
  • Patent number: 10010602
    Abstract: A fusion protein comprising an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a translocation peptide, a fusion antigen, an endoplasmic reticulum retention sequence, and optionally a nuclear export signal is disclosed. The fusion antigen comprises a porcine reproductive and respiratory syndrome virus (PRRSV) ORF7 antigen, a PRRSV ORF1b antigen, a PRRSV ORF6 antigen, and a PRRSV ORF5 antigen. The fusion protein is useful for inducing antigen-specific cell-mediated and humoral responses.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 3, 2018
    Assignee: REBER GENETICS CO., LTD.
    Inventors: Yu-Hsin Chien, Meng-Ju Tsai, Pao-Yen Lai, Wei-I Chou, Hsiu-Kang Chang
  • Patent number: 9993545
    Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 12, 2018
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David B. Weiner, Jian Yan, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Patent number: 9987350
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human Enterovirus B, Human enterovirus C, Human Enterovirus D antigens and their use in vaccines for the prevention of an enterovirus infection.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: June 5, 2018
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Patent number: 9970067
    Abstract: This invention relates to primers and probes for detecting Ebola virus and one or more subtypes of Ebola virus as well as kits including the probes and primers and methods of using the probes and primers.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 15, 2018
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Scott Rose, Kristin Beltz
  • Patent number: 9969986
    Abstract: A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: May 15, 2018
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Patent number: 9956281
    Abstract: The present invention is directed at a composition comprising a live swine flu virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. Preferably, the formaldehyde donor agent is selected from a non-crosslinking chemical fixative that contains urea.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: May 1, 2018
    Assignee: STRECK, INC.
    Inventors: Wayne L. Ryan, James A Grunkemeyer
  • Patent number: 9944904
    Abstract: This invention relates to a method for rapid production of PCV2 such that an optimum yield of the virus can be obtained. This invention also relates to the vaccine useful against PCV2 which includes the PCV2 propagated using such a method.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: April 17, 2018
    Assignee: MERIAL INC.
    Inventors: Paulraj Lawrence, Frederic Dumas
  • Patent number: 9925255
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9925256
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9919041
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9872898
    Abstract: Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: January 23, 2018
    Assignee: Ohio State Innovation Founation
    Inventors: Renukaradhya J. Gourapura, Varun Dwivedi, Basavaraj S. Binjawadagi, Jordi Torrelles
  • Patent number: 9867835
    Abstract: A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: January 16, 2018
    Assignee: ENTERIN LABORATORIES, INC.
    Inventor: Michael Zasloff
  • Patent number: 9833407
    Abstract: The present invention provides a nasal vaccine for Streptococcus pneumoniae, and a production method therefor. This nasal vaccine formulation for primates includes a complex of PspA, i.e. the vaccine antigen, and a nanogel in which hydrophobic cholesterol is added, as side chains, to pullulan having amino groups. Furthermore, the present invention provides a production method for the nasal vaccine formulation for primates.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: December 5, 2017
    Assignee: Intellectual Property Strategy Network, Inc.
    Inventors: Yoshikazu Yuki, Hiroshi Kiyono, Kazunari Akiyoshi, Shinichi Sawada
  • Patent number: 9814771
    Abstract: The role of a specific E2 region containing a putative fusion peptide (FP) sequence was evaluated. FPs critically contribute to the interaction between proteins and the membrane system of the host cell. Reverse genetics utilizing a full-length infectious clone of the highly virulent CSFV strain Brescia (BICv) was used to evaluate how amino acid substitutions within this region of E2 may affect replication of BICv in cell cultures and affect virus virulence in swine. Interestingly, mutated virus FPi.c was completely attenuated when inoculated intranasally at a dose of 105 TCID50 in swine. Importantly, animals infected with FPi.c virus were protected against the virulent challenge with Brescia virus at 3 and 28 days after vaccination. Protection was evidenced by absence of clinical signs related with CSF as well as the absence of viremia produced by the challenge virulent virus.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: November 14, 2017
    Assignees: The United States of America, as represented by The Secretary of Agriculture, The University of Connecticut, Universidad del Pais Vasco/Euskal Herriko Univertsitatea (UPV-EHU)
    Inventors: Manuel V. Borca, Douglas P. Gladue, Lauren G. Holinka-Patterson, Vivian O'Donnell, Jose Nieva
  • Patent number: 9803199
    Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: October 31, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
  • Patent number: 9795666
    Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: October 24, 2017
    Assignee: Academia Sinica
    Inventors: Pei-Wen Hsiao, Chia-Ying Wu, Yi-Chun Yeh
  • Patent number: 9796996
    Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: October 24, 2017
    Assignee: UNIVERSITEIT UTRECHT HOLDING B.V.
    Inventors: Petrus Josephus Marie Rottier, Hui-wen Chang, Herman F. Egberink
  • Patent number: 9764022
    Abstract: Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: September 19, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christopher B. Buck, Diana V. Pastrana
  • Patent number: 9758787
    Abstract: The present disclosure provides, inter alia, Thraustochytrium and relevant methods and reagents, including engineered regulatory sequences from and/or operative in Thraustochytrid or Thraustochytrium, selectable markers useful for engineering microorganisms such as Thraustochytrids, means for mutagenizing microorganisms, novel strains produced by mutagenesis, and methods and compositions related to production of particular compounds in microorganisms.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: September 12, 2017
    Assignee: DSM NUTRITIONAL PRODUCTS AG
    Inventors: ShuoCheng Zhang, Roberto E. Armenta
  • Patent number: 9751912
    Abstract: In one or a plurality of embodiments, there is provided a target molecule of amylospheroid, which is expressed in mature neurons and to which the amylospheroid binds to induce death of cells. Further, in one or a plurality of embodiments, there is provided a method and a substance for inhibiting death of mature neurons induced by the amylospheroid. In one aspect, the present disclosure relates to a use of Na+/K+-ATPase ?3 as a binding target molecule of amylospheroid. In another aspect, the present disclosure relates to a method for suppressing death of mature neurons induced by the amylospheroid, including inhibiting protein-protein interaction between the amylospheroid and the Na+/K+-ATPase ?3, and the like.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: September 5, 2017
    Assignee: TAO HEALTH LIFE PHARMA CO., LTD.
    Inventor: Minako Hoshi